

CURRICULUM VITAE

Simone Ferrero, MD



Personal data

Date of birth: September 9, 1982
Place of birth: Savigliano (CN), Italy
Citizenship: Italian
Mailing address: Divisione Universitaria di Ematologia
Via Genova 3, 10126 Torino, Italy
Fax: + 39-011-696-3737;
Phone (work): +39-011-633-4220/6884/4251
E-mail: simone.ferrero@unito.it

Education

2007

Medical degree (with distinction), University of Torino, Italy

2012

Post-graduate degree in Hematology (with distinction), University of Torino, Italy

2012

German language degree “Goethe-Zertifikat B2”, “Goethe Institut” of Berlin, Germany

2015-2017

Interuniversity, II level master classes in “Diagnosis and treatment of lymphomas”, University of Udine, Italy

Professional records

2005-2007

Internship, Division of Hematology, University of Torino, Italy

2008-2012

Post-doctoral fellow, Division of Hematology, University of Torino, Italy

2012-2016

Research fellow, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

10/2012-05/2013

Research fellow by "Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Campus Großhadern" and „Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt“ – Munich, Germany

11/2013-12/2013

Research fellow by Molecular genetics laboratory - "Universitätsklinikum S.-H. Campus Kiel 2. Medizinische Klinik und Poliklinik im Städtischen Krankenhaus" - Kiel, Germany.

09/2016-08/2017

Visiting research fellow, Division of Hematology, "SS Antonio e Biagio e C. Arrigo Hospital", Alessandria, Italy

01/12/2016-30/06/2024

Assistant Professor in Hematology, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

01/12/2016-today

Phase I Unit Study Physician, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

2018

National Scientific Abilitation, ASN 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA, II fascia

01/07/2024-today

Associate Professor in Hematology, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

Clinical activity

Clinical management of onco-hematological in- and out-patients, comprising bone marrow transplantation. Specifically focused on mature lymphoproliferative disorders, comprising patients enrollment in clinical trials.

Didactical activity

- 2020-2021 Medicine and Surgery master classes of the university of Torino ("SME0729 - Clinics and pathology of hematology and immunology")
- Frontal lessons, as support of the Medical Biotechnology master classes of the university of Torino ("INT0637A - TERAPIE BIOTECNOLOGICHE IN EMATOLOGIA", INT0637 - TERAPIE BIOTECNOLOGICHE"): 2 hours/year from 2015 to 2020
- Frontal lessons, as support of the Medicine and Surgery master classes of the university of Torino ("MED2719A - CLINICA E PATOLOGIA DEL SISTEMA EMOLINFOPOIETICO ED IMMUNITARIO"): 8 hours in 2020, 4 hours in 2021 and 2022, 6 hours in 2023.
- Supervision of several master degree students in Medicine (8), Biology (2), Medical Biotechnology (10) and Molecular Biotechnology (2).
- Frontal lessons for the interuniversity, II level master classes in "Diagnosis and treatment of lymphomas", University of Udine, Italy: 2 hours in 2019, 3 hours in 2023
- Frontal lessons for the interuniversity, I level master classes in "Management of multiple myeloma", European Myeloma Network, Torino, Italy: 1.5 hours in 2020, 2021, 2022 and 2023

Editorial activity

- Associate Editor for *HemaSphere*
- Reviewer for *Blood*, *Clinical Cancer Research*, *Leukemia*, *HemaSphere*, *Haematologica*, *Blood Advances*, *Hematological Oncology*, *British Journal of Haematology*, *Leukemia & Lymphoma*

Memberships

Italian Lymphoma Foundation (FIL), board member
FIL Minimal Residual Disease (MRD) Network, coordinator
Italian Society of Hematology (SIE)
Italian Society of Experimental Hematology (SIES)
European Hematology Association (EHA)
American Society of Hematology (ASH)
European Mantle Cell Lymphoma (MCL) Network, board member
European Consortium for Waldenstroem Macroglobulinemia (ECWM)
Euro Clonality NGS, board member
Euro MRD
Castleman Disease Collaborative Network (CDCN)
Associazione Malati Italiani di Castleman (AMICa), board member
Italian Asplenia Network

Awards and honors

2015-today Coordinator of FIL MRD network

2022-today Chairman of the Biological Study Committee of FIL

- 2023 - “Fondazione F. Calabresi Prize” for the selected manuscript in translational research: “Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial, Blood Adv 2023”, Milan, Italy
- 2023 - "Czernecki-Donelly Award" for the best manuscript published in 2022 in mantle cell lymphoma field (European MCL Network), Frankfurt, Germany
- 2020 – 2nd Prize for clinical studies „Under40 in Hematology“, Italy (SIE, Italian Society of Hematology)
- 2017 – “Janssen Prize” for the best young investigator abstract presented at the 46th Meeting of the Italian Society of Hematology (SIE)”, Roma, Italy.
- 2016 – “Young Investigator Award”, Amsterdam, Netherlands (IWMF, International Waldenström’s Macroglobulinemia Foundation)
- 2016 - “Daniele Rosa” Prize, for research in lymphoproliferative disorders, Torino, Italy
- 2015 - “Ercole Brusamolino” Prize, for lymphoma research, Napoli, Italy (FIL, Italian Lymphoma Foundation)
- 2015 – “The best scientific proposal” title, during the “FIL cantera tutorial: Malignant Lymphomas, from bench to bedside”, Lecce, Italy
- 2014 - 3rd Prize „Under40 in Hematology“, Roma, Italy (SIE, Italian Society of Hematology)

Current grant support

- 2022 – “Mantle Cell Lymphoma Research Initiative II (MCL2) Synergistic Team Award (STA)”, The Leukemia & Lymphoma Society, Rye Brook, NY (US): 3M\$ (collaborator). Title: “MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapy (MULTIPLY)”
- 2021 – “Bando Ricerca Finalizzata 2021”, Ministry of Health, Rome, Italy: 330000€ (collaborator). Title: “Minimal residual disease in follicular and mantle cell lymphoma: development and validation of novel tools and predictive models”
- 2021 – “Robert A. Kyle Career Development Award”, International Waldenström’s Macroglobulinemia Foundation (IMWF), Boston, MA, US: 157500\$ (PI). Title: “A multi-omics approach for deciphering the mechanisms of progression in premalignant IgM gammopathies: new insights from the FIL “BIO-WM” trial”
- 2021 – “Bando FIL CLUB”, Fondazione Italiana Linfomi (FIL), Italy: 280000€ (PI). Title: “Validation of *EZH2* aberrations as frontline treatment predictor in advanced follicular lymphoma: an ancillary study from FIL “FOLL12” trial (“FOLL-EZ proposal”).
- 2019 – “Fellowship Program 2019”, Gilead, Italy: 25000€ (PI). Title: “Ricostituzione immunologica del patrimonio B linfocitario e valutazione della malattia minima residua dopo trapianto autologo di cellule staminali in pazienti affetti da linfoma mantellare”.
- 2018 – “Bando Giovani Ricercatori”, Fondazione Italiana Linfomi (FIL), Italy: 100000€ (PI). Title: “Minimal residual disease (MRD) analysis by next-generation sequencing (NGS) in follicular lymphoma (FL) patients lacking a molecular marker: application to the FIL ‘FOLL12’ trial”

- 2018 – AIRC Accelerator Award (Co-investigator, PI: San Miguel Izquierdo Jesús Fernando). Title: “Understanding the mechanisms of transformation and hidden resistance of incurable haematological malignancies”, code: 22796
- 2018 – AIRC Investigator Grant (Co-investigator, PI: Alberto Zamò). Title: “The spectrum of STAT6-mutated follicular lymphoma”
- 2018 - „Bando Ricerca e Istruzione“, Fondazione Cassa di Risparmio di Torino, Torino, Italy: 15000€ (Co-investigator). Title: “Biobanca piemontese per la ricerca sui linfomi: sviluppo dell’attuale modello FIL” (RF. 2018.1284)
- 2018 – Gilead Fellowship Program: 20000€ (Co-investigator). Title: “Utilizzo di esosomi tumorali in approcci non invasivi per il monitoraggio della progressione tumorale di neoplasie B linfocitarie”
- 2017 – AIRC Investigator Grant: 500000€ (Co-investigator). Title: “Genetic landscape of HCV associated B-cell lymphomas in the era of direct acting antivirals”
- 2017 – Gilead Fellowship Program: 20000€ (Co-investigator). Title: “Attivazione dell’enzima AID mediata dagli inibitori del BCR: studio di suscettibilità allo sviluppo di instabilità genomica nei pazienti affetti da LLC”
- 2017 – International Waldenström’s Macroglobulinemia Foundation (IMWF) and the Leukemia & Lymphoma Society (LLS), Boston, MA, US: 400000\$ (Co-investigator). Title: “Non-invasive diagnostics and monitoring of MRD [minimal residual disease] and clonal evolution in Waldenström’s Macroglobulinemia”
- 2016 – “Rst, ricerca biomedica condotta da giovani ricercatori”, Fondazione Cariplo, Milano, Italy: 80000€ (Co-investigator). Title: “RNA mediated correction of aberrantly methylated tumor suppressor genes in leukemia development” (Rif. 2016-0476)
- 2016 - „Bando Ricerca e Istruzione“, Fondazione Cassa di Risparmio di Torino, Torino, Italy: 25000€ (Co-investigator). Title: “Biobanca piemontese delle neoplasie ematologiche: sviluppo di strumenti informatici di supporto alla decisione clinica” (RF. 2016.0677)
- 2015 - „Bando Ricerca e Istruzione“, Fondazione Cassa di Risparmio di Torino, Torino, Italy: 25000€ (Co-investigator). Title: “Allestimento di una biobanca per la ricerca biologica sui linfomi: il modello piemontese della Fondazione Italiana Linfomi” (RF. 2015.1044)

Spoken languages

Italian: mother tongue

English: very good in writing and speaking

German: basic in writing and speaking

French: basic in writing and speaking

Scientific interests

- Diagnosis, clinics and treatment of lymphoproliferative diseases
- Design and conduction of clinical trials in lymphoproliferative diseases
- Minimal residual disease assessment by PCR and Next Generation Sequencing in non-Hodgkin lymphoma

- Molecular pathogenesis of lymphoproliferative diseases
- Genetics of immunoglobulin genes and chromosomal translocations
- Biological prognostic factors and non-invasive diagnostics in non-Hodgkin lymphoma and Waldenstroem Macroglobulinemia
- Clinics and research of Castleman disease

Ongoing projects

Currently actively involved in several national and international working groups, mainly focusing on lymphoma research and application of molecular biotechnologies in clinics.

- The principal ongoing collaborations are the following: FIL subcommittee for biological studies (chairman), FIL subcommittee for aggressive lymphomas, FIL subcommittee for indolent lymphomas, Italian FIL MRD Network, European MCL Network, ECWM, Euro MRD, Euro Clonality Next-generation sequencing working group and Castleman Disease Collaborative Network.
- Moreover, in the past three years Dr. Ferrero participated, as PI or collaborator, in several jointed grant applications with the following collaborators: University of Pavia (IT), University of Piemonte Orientale (IT), University of Torino (both Department of Molecular Biotechnologies and Health Sciences and Department of Computer Sciences, IT), Politecnico of Torino (IT), University of Kiel (DE), University of Salamanca (ES), The Royal Marsden Cancer Diagnostic Centre, Sutton (UK) and Cancer Research UK Barts Centre, London (UK).

Scientific Production

Official H-index: 28

ORCID ID: 0000-0002-9711-1502

Scopus Author ID: 16678617000

Researcher ID: K-6189-2016

Manuscripts

1. Benevolo G, Drandi D, Villivà N, Castiglione A, Monaco F, Boccomini C, Dessì D, Califano C, Curreli L, Cavallo F, Conconi A, Gaidano G, Rossi FG, Caravita di Toritto T, Ferrante M, Mannina D, Tosi P, Pietrantuono G, Musuraca G, Merli M, Sartori R, Tani M, Freilone R, Varettoni M, **Ferrero S**. Efficacy and Safety of Bendamustine, Rituximab and Bortezomib Treatment in relapsed/refractory Waldenstrom Macroglobulinemia: results of phase 2 single arm FIL-BRB trial. *Br J Haematol*. 2024 . *In press*
2. Autore F, Tedeschi A, Benevolo G, Mattiello V, Galli E, Danesin N, Rizzi R, Olivieri J, Cencini E, Puccini B, Ferrarini I, Marino D, Bullo M, Rossini B, Motta M, Innocenti I, Fresa A, Stirparo L, Petrilli D, Pasquale R, Musto P, Scapinello G, Noto A, Peri V, Zampogna G, Hohaus S, Frustaci AM, Piazza F, **Ferrero S**, Laurenti L. First-line treatment of Waldenström's macroglobulinemia in Italy: a multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies. *Am J Hematol*, 2024. *In press*
3. Clerico M, **Ferrero S***, Alessandria B, Zaccaria GM, Genuardi E, Ragagni S, Tavarozzi R, Cavallo F, Hohaus S, Musuraca G, Carella AM, Stelitano C, Tani M, Gaidano G, Olivieri J, Usai SV, Galimberti S, Re

- F, Mian M, Castellino C, Pavone V, Evangelista A, Bruno B, Cortelazzo S, Passera R, Ladetto M. Stem Cell Collection and Hematological Recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial. *Sci Rep.* 2024 Jul 23;14(1):16946. doi: 10.1038/s41598-024-67906-w.
4. Dogliotti I, Peri V, Clerico M, Vassallo F, Musto D, Mercadante S, Ragaini S, Botto B, Levis M, Ghislieri M, Molinaro L, Mortara U, Consoli C, Lonardo A, Bondielli G, **Ferrero S**, Freilone, Ricardi U, Bruno B, Cavallo F. Real Life Clinical Outcomes of Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphomas in the rituximab era: the STRIDER study. *Cancer Med.* 2024 Jul;13(14):e7448. doi: 10.1002/cam4.7448.
 5. Pulsoni A, **Ferrero S**, Tosti ME, Luminari S, Dondi A, Cavallo F, Merli F, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJM, Rattotti S, Zilioli VR, Bolis SA, Bernuzzi P, Musuraca G, Gaidano G, Perrone T, Stelitano C, Tucci A, Corradini P, Bigliardi S, Re F, Cencini E, Mannarella C, Mannina D, Celli M, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Bomben R, Ciabatti E, Genuardi E, Drandi D, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. Local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma: final results of the FIL - "MIRO" multicenter phase II trial. *Lancet Haematol.* 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1.
 6. Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, **Ferrero S**, Rattotti S, Talamì A, Murru R, Khurana A, Mwangi R, Deodato R, Cencini E, Re F, Visco C, Feldman AL, Link BK, Torresan Delamain M, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano C, Pennese E, Habermann TM, Marcheselli L, Han S, Reis IM, Paulli M, Lossos IS, Cerhan JR, Luminari S. Marginal Zone Lymphoma International Prognostic Index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. *EClinicalMedicine.* 2024 Apr 11;72:102592. doi: 10.1016/j.eclim.2024.102592. eCollection 2024 Jun.
 7. Iannitto E, **Ferrero S**, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. *Haematologica.* 2024 Mar 14. doi: 10.3324/haematol.2023.284109
 8. Ladetto M, Tavarozzi R, Zanni M, Evangelista A, **Ferrero S**, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial. *Ann Oncol.* 2024 Jan;35(1):118-129. doi: 10.1016/j.annonc.2023.10.095.
 9. Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, **Ferrero S**, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadiant S, Eckhardt K, Zucca E, Driessen C, Renner C. The combination of ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed/refractory mantle cell lymphoma and high-risk features: A phase 1/2 trial of the European MCL network (SAKK 36/13). *EClinicalMedicine.* 2023 Sep 22;64:102221. doi: 10.1016/j.eclim.2023.102221. eCollection 2023 Oct.
 10. Levis M, **Ferrero S**, Chiappella A, Bruno B, Ricardi U (2023) Editorial: Implementation of novel drugs and modern radiotherapy in the treatment of lymphoma patients. *Front. Oncol.* 13:1273598. doi: 10.3389/fonc.2023.1273598
 11. Scheubeck G, Jiang L, Hermine O, Kluin-Nelemans HC, Schmidt C, Unterhalt M, Rosenwald A, Klapper W, Evangelista A, Ladetto M, Jerkeman M, **Ferrero S**, Dreyling M, Hoster E. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). *Leukemia.* 2023 Sep;37(9):1887-1894. doi: 10.1038/s41375-023-01977-y.

12. Arcari A, Rigacci L, Tucci A, Puccini B, Usai SV, Cavallo F, Fabbri A, Balzarotti M, Pelliccia S, Luminari S, Pennese E, Zilioli VR, Abdurraouf MM, Musuraca G, Marino D, Sartori R, Botto B, Gini G, Zanni M, Hohaus S, Tarantini G, Flenghi L, Tani M, Di Rocco A, Merli M, Vallisa D, Pagani C, Nassi L, Dessì D, **Ferrero S**, Cencini E, Bernuzzi P, Mammi C, Marcheselli L, Tabanelli V, Spina M, Merli F. A FIL cohort study of R-COMP versus R-CHOP in older patients with diffuse large B-cell lymphoma. *Blood Adv.* 2023 Aug 8;7(15):4160-4169. doi: 10.1182/bloodadvances.2023009839..
13. Garcia-Sanz R, Varettoni M, Jiménez C, **Ferrero S**, Poulain S, San-Miguel JF, Guerrera ML, Drandi D, Bagratuni T, McMaster M, Roccaro AM, Roos-Weil D, Leiba M, Li Y, Qiu L, Hou J, Fernandez De Larrea C, Castillo JJ, Dimopoulos M, Owen RG, Treon SP, Hunter Z. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia. *Semin Hematol.* 2023 Mar;60(2):90-96. doi: 10.1053/j.seminhematol.2023.03.007.
14. Tisi MC, Moia R, Patti C, Evangelista E, **Ferrero S**, Spina M, Tani M, Botto B, Celli M, Puccini B, Cencini E, Di Rocco A, Chini C, Ghiggi C, Zambello R, Zanni M, Sciarra R, Bruna R, Ferrante M, Pileri S, Quaglia FM, Stelitano C, Re A, Volpetti S, Zilioli VR, Arcari A, Merli F, Visco C. Long term follow-up of Rituximab plus Bendamustine and Cytarabine (R-BAC) in elderly patients with newly diagnosed MCL. *Blood Adv.* 2023 Aug 8;7(15):3916-3924. doi: 10.1182/bloodadvances.2023009744.
15. Zinzani PL, Paulli M, Arcaini L, Della Torre E, **Ferrero S**, Figuera A, Frigeri F, Martelli M, Sabattini E, Scarpa R, Barosi G. Unmet clinical needs in the management of idiopathic multicentric Castleman disease: a consensus-based position paper from an ad hoc expert panel. *Hemasphere.* 2023 May 23;7(6):e891. doi: 10.1097/HS9.0000000000000891.
16. **Ferrero S**, Grimaldi D, Arrigoni E, Pironti M, Zaccaria GM, Alessandria B, Genuardi E, De Luca G, Ghislieri M, Tavarozzi R, Di Rocco A, Re A, Stefoni V, Cavallo F, Boccomini C, Balzarotti M, Zilioli V, Moita F, Arcaini L, Lucchini E, Ballerini F, Ferreri AJM, Puccini B, Palumbo GA, Galimberti S, Cortelazzo S, Di Paolo A*, Ladetto M. Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. *Blood Adv.* 2023 Jul 25;7(14):3764-3774. doi: 10.1182/bloodadvances.2022009504.
17. Gkoliou G, Agathangelidis A, Karakatsoulis G, Lalayianni G, Papalexandri A, Medina A, Genuardi E, Hatjiharissi E, Papaioannou M, Terpos E, Jimenez C, Sakellari I, **Ferrero S**, Ladetto M, Garcia Sanz R, Belessi C, Stamatopoulos K. Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories. *Front. Oncol.* 2023. *In press.* DOI: 10.3389/fonc.2023.1123029
18. Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, Perez JJ, Drandi D, Puig N, Gilestro M, García-Álvarez M, Owen R, Jurczak W, Tedeschi A, Leblond V, Kastritis E, Kersten MJ, D'Sa S, Kaščák M, Willenbacher W, Roccaro A, Poulain S, Morel P, Kyriakou C, Fend F, Vos J, Dimopoulos M, Buske C, **Ferrero S**, García-Sanz R. Diagnostics in Waldenström's Macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. *Leukemia.* 2022. *In press*
19. Alcoceba M, García-Álvarez M, Okosun J, **Ferrero S**, Ladetto M, Fitzgibbon J, García-Sanz R. Genetics of Transformed Follicular Lymphoma. *Hemato.* 2022. *In press*
20. Varettoni M, Zibellini S, Merli M, Drandi D, Jiménez C, Furlan D, Ferretti VV, Fabbri N, Dogliotti D, Varraso C, Ferrante M, Cappello E, Cavalloni C, Facchetti GV, **Ferrero S**, Arcaini L, Garcia-Sanz R. Molecular remission is an independent predictor of progression-free survival in patients with Waldenström Macroglobulinemia treated with chemo-immunotherapy: results from the FIL_BIOWM study. *Hematological Oncology.* 2022. *In press*
21. **Ferrero S**, Genuardi E. Looking for a needle in the haystack of CLL. *Blood.* 2022. *In press*

22. Parisi M*, Dogliotti I*, Clerico M, Bertuzzo D, Benevolo G, Orsucci L, Schiavetti I, Cavallo R, Cavallo F, Ragaini S, Di Liberto A, Ferrante M, Bondielli G, Artusi CA, Drandi D, Lopiano L, Ferrero B*, **Ferrero S**. Efficacy of Rituximab in anti-Myelin Associated Glycoprotein demyelinating polyneuropathy: clinical, haematological and neurophysiological correlations on 2-years follow up. European Journal of Neurology. 2022. *In press*.
23. **Ferrero S**, Grimaldi D, Genuardi E, Drandi D, Zaccaria GM, Alessandria B, Ghislieri M, Ferrante M, Evangelista A, Mantoan B, De Luca G, Stefani PM, Benedetti F, Casaroli I, Zanni M, Castellino C, Pavone V, Petrini M, Re F, Hohaus S, Musuraca G, Cascavilla N, Ghiggi C, Liberati AM, Cortelazzo S, Ladetto M. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma. Blood. 2022. *In press*.
24. Drandi D, Decruyenaere P, Ferrante M, Offner F, Vandesompele J, **Ferrero S**. Nucleic acid biomarkers in Waldenström macroglobulinemia and IgM-MGUS: current insights and clinical relevance. Diagnostics 2022. *In press*.
25. Zinzani PL, Martelli M, **Ferrero S**, Gentile M, Laurenti L, Mauro FR, Sportoletti P, Tedeschi A, Varettoni M, Visco C. Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: an expert panel opinion statement. Hematological Oncology. 2022. *In press*.
26. **Ferrero S**, Gentile M, Laurenti L, Mauro FR, Martelli M, Sportoletti P, Visco C, Zinzani PL, Tedeschi A, Varettoni M. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: an expert panel opinion statement. Hematological Oncology. 2022. *In press*.
27. Clerico M, Dogliotti I, Ghione P, Zilioli VR, Merli F, Botto B, Al Essa W, Battaglini M, Grimaldi D, Cervi L, Ragaini S, **Ferrero S**, Peri V, De Luca G, Marzano A, Cavallo F. HBV reactivation in patients with past infection affected by non-Hodgkin lymphoma and treated with anti-CD20 antibody based immuno-chemotherapy: a multicenter experience. Journal of Personalized Medicine. 2022. *In press*.
28. Maisano D, Mimmi S, Dattilo V, Marino F, Gentile M, Vecchio E, Fiume G, Nisticò N, Aloisio A, Penelope de Santo M, Desiderio G, Musolino V, Nucera S, Sbrana F, Andò F, **Ferrero S**, Morandi A, Bertoni F, Quinto I, Iaccino E. A novel phage display based platform for exosome diversity characterization. Nanoscale. 2022. *In press*.
29. Zaccaria GM, **Ferrero S**, Hoster E, Passera R, Evangelista A, Genuardi E, Drandi D, Ghislieri M, Barbero D, Del Giudice I, Tani M, Moia R, Volpetti S, Cabras MG, Di Renzo N, Merli F, Vallisa D, Spina M, Pascarella A, Latte G, Patti C, Fabbri A, Guarini A, Vitolo U, Hermine O, Kluin-Nelemans HC, Cortelazzo S, Dreyling M, Ladetto M. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. Cancers (Basel). 2021 Dec 31;14(1):188. doi: 10.3390/cancers14010188.
30. Zaccaria GM, Colella V, Colucci S, Clemente F, Pavone F, Vegliante MC, Esposito F, Opinto G, Scattone A, Loseto G, Minoia C, Rossini B, Quinto AM, Angiulli V, Grieco LA, Fama A, **Ferrero S**, Moia R, Di Rocco A, Quaglia FM, Tabanelli V, Guarini A, Ciavarella S. Electronic Case Report Forms generation from pathology reports by ARGO, Automatic Record Generator for Onco-hematology. Sci Rep 2021. *In press*.
31. Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, **Ferrero S**, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M, Fondazione Italiana Linfomi. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. J Clin Oncol. 2021 Oct 28;JCO2101234. doi: 10.1200/JCO.21.01234.
32. Stewart JP, Gazdova J, Darzentas N, Wren D, Proszek P, Fazio G, Songia S, Alcoceba M, Sarasquete ME, Villarese P, van der Klift MY, Heezen KC, McCafferty N, Pal K, Catherwood M, Kim CS, Srivastava S, Kroese LI, Hodges E, Stamatopoulos K, Klapper W, Genuardi E, **Ferrero S**, van den Brand M, Cazzaniga G, Davi F, Sutton LA, Garcia-Sanz R, Groenen PJTA, Macintyre EA, Brüggemann M, Pott C,

- Langerak AW, Gonzalez D; EuroClonality-NGS Working Group. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. *Blood Adv.* 2021 Aug 24;5(16):3188-3198. doi: 10.1182/bloodadvances.2020004056.
33. Mantoan B, Genuardi E, Ferrante M, Della Starza I, Ciabatti E, Grassi S, De Novi LA, Cavalli M, Mannu C, Gazzola A, Bomben R, Degan M, Alessandria B, Pott C, Delfau-Larue MH, Garcia Sanz R, Agostinelli C, Gattei V, Galimberti S, Del Giudice I, Ladetto M, **Ferrero S**, Drandi D on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network. Quality assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 years of cross-lab standardization process within the Fondazione Italiana Linfomi MRD Network. *HemaSphere*. 2021. *In press*
34. Tarella C, Cortelazzo S, Mian M, Evangelista A, Devizzi L, Corradini P, Magni M, Ladetto M, **Ferrero S**, Rossi A, Barbui AM, Patti C, Costa A, Vitolo U, Chiappella A, Benedetti F, Ferreri A, Nicoli P, Rigacci L, Castellino C, Gianni AM, Rambaldi A. Upfront Intensive Chemo-immunotherapy with Autograft in 199 Adult Mantle Cell Lymphoma Patients: prolonged survival and cure potentiality at long term. *Bone Marrow Transplant*. 2021. *In press*.
35. Clerico M*, Dogliotti I*, Calcagno A, Grimaldi D, Leone S, Ragaini S, Boffini M, Caracciolo D, **Ferrero S**, Barbero C, Zanotto E, Stroffolini G, Cavallo R, Rinaldi M, Bruno B, Cavallo F. Covid-19 in a post-transplant heart recipient who developed aggressive lymphoma: a biphasic course during rituximab treatment. *Hemasphere*. 2021 Jun 12;5(7):e592. doi: 10.1097/HS9.0000000000000592
36. Ferrante M, Furlan D, Zibellini S, Borriero M, Candido C, Sahnane N, Uccella S, Genuardi E, Alessandria B, Bianchi B, Mora B, Grimaldi D, Defrancesco I, Jimenez C, Cavallo F, Ferrero D, Dogliotti I, Merli M, Varettoni M, **Ferrero S***, Drandi D. *MYD88L265P* detection in IgM monoclonal gammopathies: methodological considerations for routine implementation. *Diagnostics (Basel)*. 2021 Apr 26;11(5):779. doi: 10.3390/diagnostics11050779
37. Genuardi E, Romano G, Beccuti M, Alessandria B, Mannina D, Califano C, Rota Scalabrini D, Cortelazzo S, Ladetto M, **Ferrero S***, Calogero RA, Cordero F. Application of the Euro Clonality NGS based marker screening approach to detect IGH rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. *Br J Haematol*. 2021 May 18. doi: 10.1111/bjh.17519.
38. Dogliotti I, Ragaini S, Vassallo F, Boccellato E, De Luca G, Perutelli F, Boccomini C, Clerico M, Botto B, Grimaldi D, Orsucci L, **Ferrero S**, Vitale C, Ferrero D, Coscia M, Cavallo F. Real life use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. *Journal of Personalized Medicine*. 2021. *In press*
39. Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, Alessandria B, Dogliotti I, Grimaldi D, Ragaini S, Clerico M, Lo Schirico M, Saraci E, Yilmaz M, Zaccaria GM, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, van Min M, Splinter E, Ladetto M, **Ferrero S**. Targeted Locus Amplification to Detect Molecular Markers in Mantle Cell and Follicular Lymphoma. *Hematol Oncol*. 2021 Mar 20. doi: 10.1002/hon.2864.
40. **Ferrero S**, Ragaini R. Dichotomic response to IL-6 blockade in idiopathic multicentric Castleman disease: report of two cases. *J Med Case Rep*. 2021 Mar 7;15(1):105. doi: 10.1186/s13256-021-02726-4.
41. Marangon M, Visco C, Barbui AM, Chiappella A, Fabbri A, **Ferrero S**, Galimberti S, Luminari S, Musuraca G, Re A, Zilioli VR, Ladetto M. Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy. *Cancers (Basel)*. 2021 Jan 14;13(2):291. doi: 10.3390/cancers13020291
42. Merli F, Luminari S, Tucci A, Arcari A, Rigacci L, Hawkes E, Chiattone CS, Cavallo F, Cabras G, Alvarez I, Fabbri A, Re A, Puccini B, Barraclough A, Torresan Delamain M, **Ferrero S**, Usai SV, Ferrari A, Cencini E, Pennese E, Zilioli V, Marino D, Balzarotti M, Cox C, Zanni M, Di Rocco A, Lleshi A, Botto B, Hohaus S, Merli M, Sartori R, Gini G, Nassi L, Musuraca G, Tani M, Bottelli C, Kovalchuk S, Re F, Flenghi L, Molinari A, Tarantini G, Chimienti C, Marcheselli L, MammiC, Spina M. Simplified comprehensive geriatric

- assessment in the initial evaluation of elderly patients with diffuse large B-cell lymphoma: final results of the prospective Elderly Project of the Fondazione Italiana Linfomi. *Journal Clin Oncol*. 2021. *In press*.
43. Boccomini C, Ladetto M, Rigacci L, Puccini B, Rattotti S, Volpetti S, **Ferrero S**, Chiarenza A, Freilone R, Novo M, Corradini P, Nassi L, Rusconi C, Stelitano C, Bolis S, Liberati AM, Tucci A, Baldini L, Balzarotti M, Evangelista A, Ciccone G, Vitolo U. A Brief Rituximab, Bendamustine, Mitoxantrone (R-BM) induction followed by Rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). *Br J Haematol*. 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283
44. Pierson S, Khor J, Ziglar J, Liu A, Floess K, NaPier E, Gorzewski A, Tamakloe M, Powers V, Akhter F, Haljasmaa E, Jayanthan R, Rubenstein A, Repasky M, Elenitoba-Johnson K, Ruth J, Jacobs B, Streetly M, Angenendt L, Patier JL, **Ferrero S**, Zinzani PL, Terriou L, Casper C, Jaffe E, Hoffmann C, Oksenhendler E, Fossà A, Srkalovic G, Chadburn A, Uldrick T, Lim M, van Rhee F, Fajgenbaum D. ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder. *Cell Rep Med*. 2020 Dec 22;1(9):100158. doi: 10.1016/j.xcrm.2020.100158
45. **Ferrero S**, Grimaldi D, Dreyling M on behalf of European Mantle Cell Lymphoma Network. Tailored treatment in mantle cell lymphoma. *Annals of Lymphoma*. 2021 *In press*.
46. Ladetto M, Cortelazzo S, **Ferrero S**, Evangelista A, Mian M, Tavarozzi R, Zanni M, Cavallo F, Di Rocco A, Stefoni V, Rossi G, Chiappella A, Balzarotti M, Zilioli V, Gomes Da Silva M, Arcaini L, Molinari AL, Ballerini F, Ferreri A, Bosi A, Benedetti F, Stefani PM, Narni F, Casaroli I, Stelitano C, Ciccone G, Vitolo U, Martelli M. Lenalidomide maintenance after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma (MCL): Results of a “Fondazione Italiana Linfomi” (FIL) multicenter randomised phase III trial. *Lancet Haematol*. 2021 Jan;8(1):e34-e44. doi: 10.1016/S2352-3026(20)30358-6.
47. Fajgenbaum D, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, **Ferrero S**, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease American Journal of Hematology 2020. *In press*. DOI:10.1002/ajh.25992
48. Della Starza I, De Novi LA, Cavalli M, Novelli N, Genuardi E, Mantoan B, Drandi D, Ferrante M, Monitillo L, Barbero D, Ciabatti E, Grassi S, Bomben R, Degan M, Gattei, Galimberti S, Di Rocco A, Martelli M, Cortelazzo S, Guarini A, Foà R, Ladetto M, **Ferrero S**, Del Giudice I. On behalf of the Fondazione Italiana Linfomi (FIL) MRD Network. Immunoglobulin kappa deleting element (IGK-KDE) rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. *Hematol Oncol*. 2020 Dec;38(5):698-704. doi: 10.1002/hon.2792.
49. Varettoni M, Ferrari A, Frustaci AM, Ferretti VV, Rizzi R, Motta M, Piazza F, Merli M, Benevolo G, Visco C, Laurenti L, **Ferrero S**, Gentile M, Del Fabro V, Abbadessa A, Klerys C, Musto P, Fabbri N, Deodato M, Dogliotti I, Greco C, Corbingi A, Luminari S, Arcaini L. Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. *Am J Hematol*. 2020 Dec;95(12):1473-1478. doi: 10.1002/ajh.25961.
50. Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, **Ferrero S**, Alvarez De Celis MI, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, Vitolo U, Balzarotti M. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. *Leukemia*. 2021 Mar;35(3):787-795. doi: 10.1038/s41375-020-01013-3.
51. Apolito V, Giaccone L, **Ferrero S**, Larocca A, Cavallo F, Coscia M, Beggiato E, Scaldaferri M, Cattel F, Boccadoro M, Ferrero D, Bruno B, Cerrano M. Netupitant-Palonosetron to Prevent Chemotherapy-Induced Nausea and Vomiting in Multiple Myeloma Patients Receiving High-Dose Melphalan and Autologous Stem Cell Transplantation. *Ann Hematol*. 2020 Jul 13. doi: 10.1007/s00277-020-04180-6.

52. Mondello P, Musolino C, Dogliotti I, Bohn JP, Cavallo F, **Ferrero S**, Botto B, Cerchione C, Nappi D, De Lorenzo S, Martinelli G, Wolf D, Schmitt C, Loseto G, Cuzzocrea S, Willenbacher W, Mian M, Straus DJ. ABVD versus BEACOPP escalated in Advanced-Stage Hodgkin's Lymphoma: results from a multicenter European study. *Am J Hematol.* 2020 May 17. doi: 10.1002/ajh.25871.
53. Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria GM, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Della Starza I, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, **Ferrero S**, Macintyre E. Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. *Hemisphere.* 2020 Apr 4(2):e347 doi: 10.1097/HS9.0000000000000347
54. Lo Schirico M, Ferrante M, Dogliotti I, Zamò A, Ferrero B, Bertuzzo D, Benevolo G, Omedè P, Cavallo F, Ladetto M, Boccadoro M, Drandi D and **Ferrero S**. Droplet digital PCR assay for *MYD88L265P*: clinical applications in Waldenström Macroglobulinemia. *Hemisphere.* 2020 Jan 3;4(1):e324. doi: 10.1097/HS9.0000000000000324.
55. Tisi MC*, **Ferrero S***, Dogliotti I, Tecchio C, Carli G, Novo M, Stefani PM, Rattotti S, Balzarotti M, Marino D, Pelosini M, Romano A, Flenghi L, Zilioli VR, Calimeri T, Di Napoli A, Zanni M, Finolezzi E, Mosna F, Gini G, Mansueti G, Di Rocco A, Tomei G, Sgherza N, Olivieri J, Nassi L, Piazza F, Fama A, Greco A, Giannoccaro M, Mazzone AM, Visco C, Loseto G, and Zaja F, on behalf of the Fondazione Italiana Linfomi Postgraduate Master course. MYC Rearranged Aggressive B-Cell Lymphomas: a report on 100 patients of the Fondazione Italiana Linfomi (FIL). *Hemisphere.* 2019 Oct 22;3(6):e305. doi: 10.1097/HS9.0000000000000305.
56. Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K, Moita F, Marino D, **Ferrero S**, Szymczyk M, Aurer I, El-Galaly TC, Di Rocco A, Visco C, Carli G, Defrancesco I, Carlo-Stella C, Dreyling M, Santoro A and Arcaini L. Mantle cell lymphoma of mucosa-associated lymphoid tissue: a European Mantle Cell Lymphoma Network study. *Hemisphere.* 2019 Dec 16;4(1):e302. doi: 10.1097/HS9.0000000000000302.
57. **Ferrero S***, Rossi D*, Rinaldi A*, Bruscaggin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Steffoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, Gomes da Silva M, Santoro A, Molinari A, Ferreri A, Grønbæk K, Piccin A, Cortelazzo S, Bertoni F°, Ladetto M° and Gaidano G°. *KMT2D* mutations and *TP53* disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. *Haematologica* September 2019: haematol.2018.214056; doi: 10.3324/haematol.2018.214056
58. Zaccaria GM, **Ferrero S**, Rosati S, Ghislieri M, Genuardi E, Evangelista A, Sandrone E, Castagneri C, Barbero D, Lo Schirico M, Arcaini A, Molinari AL, Ballerini B, Ferreri A, Omedè P, Zamò A, Balestra G, Boccadoro M, Cortelazzo S and Ladetto M. Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. *JCO Clin Cancer Inform.* 2019 Oct;3:1-15. doi: 10.1200/CCI.19.00049.
59. Della Starza I, Cavalli M, De Novi L.A, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, **Ferrero S** and Del Giudice I, on behalf of the Fondazione Italiana Linfomi (FIL) MRD Network. Minimal residual disease (MRD) in non-Hodgkin lymphomas: inter-laboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. *Hematol Oncol.* 2019 Jul 19. doi: 10.1002/hon.2652.
60. Merli F, Cavallo F, Salvi F, Tucci A, Musuraca G, Nassi L, Merli M, Tani M, Gini G, Ferrari A, Molinari AL, Liberati AM, Conconi A, Matteucci P, Bari A, Scalzone R, **Ferrero S**, Zanni M, Mammi C, Luminari S. Obinutuzumab and miniCHOP for Elderly Unfit Patients with Diffuse Large B-Cell Lymphoma. A Phase II study by Fondazione Italiana Linfomi. *J Geriatr Oncol.* 2019 Jul 8. pii: S1879-4068(18)30482-X. doi: 10.1016/j.jgo.2019.06.020.
61. Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F, Varettoni M, Bianchi B, Merli F, Tedeschi A, Cabras G, Re F, Visco C, Delamain MT, Fabbri A, Spina M, **Ferrero S**, Ferrari A, Deodato M, Mannina D, Annibali O, Cimino G, Orsucci L, Frigeni M, Cesaretti M, Arcaini L. Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the NF10 Study By Fondazione Italiana Linfomi. *Blood.* 2019 Sep 5;134(10):798-801. doi: 10.1182/blood.2019001088.

62. D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Dal Bo M, **Ferrero S**, Ladetto M, Zamò A, Gattei V, Bomben R. A B-cell receptor-related gene signature predicts response to ibrutinib treatment in Mantle Cell Lymphoma cell lines. *Haematologica*. 2019 Sep;104(9):e410-e414. doi: 10.3324/haematol.2018.212811.
63. Grimaldi D, Genuardi E, Ferrante M, **Ferrero S**, Ladetto M. Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. *Curr Treat Options Oncol*. 2018 Nov 6;19(12):71. doi: 10.1007/s11864-018-0594-1
64. Visco C, Maria Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, **Ferrero S**, Puccini B, De Celis IA, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosi M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hostetler E, Vitolo U. Time to Progression of Mantle Cell Lymphoma After High Dose Cytarabine Based Regimens Defines Patients Risk for Death. *Br J Haematol*. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643.
65. Dogliotti I, Drandi D, Genuardi E, **Ferrero S**. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. *J Clin Med*. 2018 Sep 18;7(9). pii: E288. doi: 10.3390/jcm7090288
66. Drandi D, **Ferrero S**, Ladetto M. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. *Methods Mol Biol*. 2018;1768:229-256. doi: 10.1007/978-1-4939-7778-9_14.
67. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi NC, Schey SA, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan RK, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson K, Krymskaya V, Goodman AM, Hoffmann C, Zinzani PL, **Ferrero S**, Terriou L, Sato Y, Simpson DR, Wong RS, Rossi JF, Nasta SD, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, Evidence-based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease. *Blood*. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334.
68. Tonialini L, Bonfichi M, **Ferrero S**, Malipiero G, Nozza A, Argnani L, Zinzani PL. Siltuximab in relapsed/refractory multicentric Castleman disease: experience of the Italian NPP program. *Hematol Oncol*, 2018; 1-4. doi: 10.1002/hon.2532
69. Olivieri J, Mosna F, Pelosi M, Fama A, Rattotti S, Giannoccaro M, Carli G, Tisi MC, **Ferrero S**, Sgherza N, Mazzzone AM, Marino D, Calimeri MT, Loseto G, Saraceni F, Tomei G, Sica S, Perali G, Codeluppi K, Billio A, Olivieri A, Orciuolo E, Matera R, Stefani PM, Borghero C, Ghione P, Cascavilla N, Lanza F, Chiusolo P, Finotto S, Federici I, Gherlinzoni F, Centurioni R, Fanin R, Zaja F, on behalf of the Fondazione Italiana Linfomi Postgraduate Master course. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi (FIL). *Biol Blood Marrow Transplant*. 2018 May 29. pii: S1083-8791(18)30270-2. doi: 10.1016/j.bbmt.2018.05.018.
70. Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, **Ferrero S**, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L and Zinzani PL. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. *Oncotarget*. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215.
71. Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jiménez C, Guerrini F, Lo Schirico M, Mantoan B, Muccio V, Lia G, Zaccaria GM, Omedè P, Passera R, Orsucci L, Benevolo G, Cavallo F, Galimberti S, García Sanz R, Boccadoro M, Ladetto M and **Ferrero S**. Highly sensitive MYD88^{L265P} mutation detection by droplet digital PCR in Waldenström Macroglobulinemia. *Haematologica*. 2018 Mar 22. pii: haematol.2017.186528. doi: 10.3324/haematol.2017.186528.
72. Bomben R*, **Ferrero S***, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Delong L, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M*, Gattei V*. A B-cell receptor-related gene signature predicts survival in Mantle Cell Lymphoma:

- results from the FIL-MCL-0208 trial. *Haematologica*. 2018 Feb 22. pii: haematol.2017.184325. doi: 10.3324/haematol.2017.184325.
73. Mondello P, Cerchione C, Steiner N, Willenbacher W, Nappi D, Mauro E, **Ferrero S**, Cuzzocrea S, Mian M. Bendamustine plus Rituximab versus R-CHOP as first-line treatment for patient with Follicular Lymphoma Grade 3A: evidence from a multicenter, retrospective study. *Oncologist*. 2018 Jan 9. pii: theoncologist.2017-0037. doi: 10.1634/theoncologist.2017-0037.
74. Beccuti M, Genuardi E, Romano G, Monitillo L, Barbero D, Boccadoro M, Ladetto M, Calogero RA, **Ferrero S***, Cordero F*. HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. *BMC Bioinformatics*. 2017 Nov 23;18(1):516. doi: 10.1186/s12859-017-1923-2
75. Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, **Ferrero S** on behalf of Fondazione Italiana Linfomi (FIL) MRD Network. Ficoll-Hypaque separation versus whole blood lysis: comparison of efficiency and impact on minimal residual disease analysis. *Int J Lab Hematol*. 2017 Dec 4. doi: 10.1111/ijlh.12766
76. **Ferrero S**, Dreyling M, on behalf of European Mantle Cell Lymphoma Network. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? *Haematologica*. 2017 Jul;102(7):1133-1136. doi: 10.3324/haematol.2017.167627
77. Dogliotti I, **Ferrero S**. Personalized medicine in lymphoma: tailoring treatment according to minimal residual disease. *Medical Research Archives*, Vol. 5, Issue 4, April 2017. doi: <http://dx.doi.org/10.18103/mra.v5i4.1097>.
78. Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo, Cerri M, Ruggeri M, Omedè P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, **Ferrero S**. Progressive telomere shortening is part of the natural history of chronic lymphocytic leukemia and impacts clinical outcome: evidences from long term follow-up. *British Journal of Hematology*, 2017 Apr 2. doi: 10.1111/bjh.14681.
79. Zaja F, **Ferrero S**, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Ladetto M, Carmichael J, Fanin R. Second-line rituximab, lenalidomide, and bendamustine (R2B) in relapsed or refractory MCL: a phase 2 clinical trial. *Haematologica*. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211.
80. Visco C, Chiappella A, Nassi L, Patti C, **Ferrero S**, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. *Lancet Haematol*. 2016 Dec 2. pii: S2352-3026(16)30185-5. doi: 10.1016/S2352-3026(16)30185-5.
81. Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, **Ferrero S**, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. *Oncotarget*. 2016 Oct 13. doi: 10.18632/oncotarget.12641.
82. Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Endri M, **Ferrero S**, Ghione P, Pitini V, Cuzzocrea S and Mian M. Bendamustine plus Rituximab versus R-CHOP as first-line treatment for patient with Indolent Non-Hodgkin's Lymphoma: evidence from a multicenter, retrospective study. *Annals of Hematology* 2016 Jun;95(7):1107-14. doi: 10.1007/s00277-016-2668-0.
83. Mondello P, Steiner N, Willenbacher W, **Ferrero S**, Ghione P, Marabese A, Pitini V, Cuzzocrea S and Mian M. Lenalidomide in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Is It a Valid Treatment option?. *The Oncologist*. 2016 Jul 5. pii: theoncologist.2016-0103.
84. Dreyling M, **Ferrero S**; European Mantle Cell Lymphoma Network. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?. *Haematologica*. 2016 Feb;101(2):104-14. doi: 10.3324/haematol.2014.119115

85. Ladetto M, **Ferrero S**, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M and Bruno B. Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma. *Leukemia*. 2015 Oct 6. doi: 10.1038/leu.2015.269
86. **Ferrero S**, Pastore A, Scholz CW Forstpointner R, Pezzutto A, Bergmann L, Truemper L, Finke J, Keller U, Ghione G, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial. *Leukemia*. 2015 Aug 5. doi: 10.1038/leu.2015.215.
87. Riera L, Osella-Abate S, Benevolo G, Beggiato E, **Ferrero S**, Pich A, and Francia di Celle P. Novel CALR somatic mutations in essential thrombocytemia. *British Journal of Hematology* 2015 Sep 7. doi: 10.1111/bjh.13638.
88. Drandi D, Kubiczkova-Besse L, **Ferrero S**, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G and Ladetto M. Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma and follicular lymphoma: a comparison with real-time PCR. *J Mol Diagn*. 2015 Aug 26. pii: S1525-1578(15)00147-6. doi: 10.1016/j.jmoldx.2015.05.007.
89. Dreyling M, **Ferrero S**; European Mantle Cell Lymphoma Network. Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. *Haematologica*. 2015 Jun;100(6):706-8. doi: 10.3324/haematol.2015.127472.
90. Tedeschi A, Picardi P, **Ferrero S**, Benevolo G, Casaluci Margiotta G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E. (2015). Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström's macroglobulinemia. *LEUKEMIA & LYMPHOMA*, ISSN: 1042-8194
91. Dreyling M, **Ferrero S**, Vogt N, Klapper W, on behalf of European Mantle Cell Lymphoma Network. New paradigms in Mantle Cell Lymphoma: is it time to risk stratify treatment based on the proliferative signature? *Clinical Cancer Research*. 2014 Clin Cancer Res. 2014 Oct 15;20(20):5194-206. doi: 10.1158/1078-0432.CCR-14-0836.
92. Dreyling M, **Ferrero S**; European Mantle Cell Lymphoma Network. How to treat old MCL patients: one size fits it all? *Blood*. 2014 Aug 21;124(8):1207-8. doi: 10.1182/blood-2014-06-578872.
93. **Ferrero S***, Ladetto M*, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Pia Falcone A, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A. Long-term results of the gimema vel-03-096 trial in mm patients receiving vtd consolidation after asct: mrd kinetics impact on survival. *LEUKEMIA*. 2014 Jul 16. doi: 10.1038/leu.2014.219.
94. Dreyling M, **Ferrero S**, Hermine O. How I manage mantle cell lymphoma. *LEUKEMIA*. 2014 May 23. doi: 10.1038/leu.2014.171. [Epub ahead of print]
95. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz J, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, **Ferrero S**, Inghirami G, Horwitz SM, Weinstock DM. (2013). A Targeted Mutational Landscape of Angioimmunoblastic T cell Lymphoma. *BLOOD*. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509.
96. Ladetto M, Brüggemann M, Monitillo L, **Ferrero S**, Pepin F, Drandi D, Barbero D, Palumbo A, Passera R, Boccadoro M, Ritgen M, Gökbüget N, Zheng J, Carlton V, Trautmann H, Faham M, Pott C. (2013) Next-generation sequencing and Real-Time Quantitative PCR for minimal residual disease (MRD) detection using the immunoglobulin heavy chain variable region: a methodical comparison in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and multiple myeloma (MM). *LEUKEMIA*. 2013 Dec 17. doi: 10.1038/leu.2013.375
97. **Ferrero S**, Monitillo L, Mantoan B, Barbero D, Genuardi E, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Gueli A, Renna F, Lobetti Bodoni C, Barbiero S, Musto P, Boccadoro M, Tarella C, Ladetto M

- (2013). Pre-emptive rituximab-based treatment of molecular relapses in follicular and mantle cell lymphoma. *ANNALS OF HEMATOLOGY*. Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y
98. **Ferrero S**, Dreyling M (2013). The current therapeutic scenario for relapsed mantle cell lymphoma. *CURRENT OPINION IN ONCOLOGY*. Sep;25(5):452-62.
 99. Pregno P, Chiappella A, Bellò M, Botto B, **Ferrero S**, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U. (2012). The interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. *BLOOD*, vol. Jan 10., ISSN: 0006-4971
 100. **Ferrero S**, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, Ladetto M. (2011). Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. *HAEMATOLOGICA*, vol. Dec 29., ISSN: 0390-6078
 101. Lamorte S, **Ferrero S**, Aschero S, Monitillo L, Bussolati B, Omedè P, Ladetto M, Camussi G. (2011). Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cell.. *LEUKEMIA*, vol. Oct 25, ISSN: 0887-6924, doi: 10.1038/leu.2011.290
 102. **FERRERO S**, DRANDI D, MANTOAN B, GHIONE P, OMEDÈ P AND LADETTO M (2011). Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. *HEMATOLOGICAL ONCOLOGY*, vol. 29, p. 167-176, ISSN: 0278-0232, doi: 10.1002/hon.989
 103. LADETTO M, **FERRERO S**, BARBIERO S (2011). La terapia del linfoma mantellare: un esempio di integrazione tra biologia e clinica. *SEMINARI DI EMATOLOGIA ONCOLOGICA*, vol. 8
 104. LADETTO M, PAGLIANO G, **FERRERO S**, CAVALLO F, DRANDI D, SANTO L, CRIPPA C, DE ROSA L, PREGNO P, GRASSO M, LIBERATI AM, CARAVITA T, PISANI F, GUGLIELMELLI T, CALLEA V, MUSTO P, CANGIALOSI C, PASSERA R, BOCCADORO M, PALUMBO A (2010). Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. *JOURNAL OF CLINICAL ONCOLOGY*, vol. 28(12), p. 2077-2084, ISSN: 0732-183X
 105. ROSSI D, LOBETTI BODONI C, GENUARDI E, MONITILLO L, DRANDI D, CERRI M, DEAMBROGI C, RICCA I, ROCCI A, **FERRERO S**, BERNOCCO E, CAPELLO D, DE PAOLI L, BERGUI L, BOI M, OMEDÈ P, MASSAIA M, TARELLA C, PASSERA R, BOCCADORO M, GAIDANO G, LADETTO M (2009). Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. *LEUKEMIA*, vol. 23(6), p. 1062-1072, ISSN: 0887-6924

Book chapters

1. Drandi D, Ferrante M, Borriero M, **Ferrero S**. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring. *Methods Mol Biol* 2023;2621:57-72. doi: 10.1007/978-1-0716-2950-5_5.
2. Genuardi E, Alessandria B, Civita AM, **Ferrero S**. Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas. *Methods Mol Biol*. 2022;2453:119-132. doi: 10.1007/978-1-0716-2115-8_8.
3. Drandi D, **Ferrero S**, Ladetto M. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. *Methods Mol Biol*. 2018;1768:229-256. doi: 10.1007/978-1-4939-7778-9_14.
4. **Ferrero S** and Dreyling M. The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. © Springer-Verlag London 2015 U. Wedding, R.A. Audisio (eds.), *Management of Hematological Cancer in Older People*, DOI 10.1007/978-1-4471-2837-3_9. 2013

Autorizzo il trattamento dei dati personali ai sensi del GDPR e del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" ai fini di attività di Ricerca e Selezione del Personale e contatti lavorativi.

In compliance with the GDPR and the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document

Torino, 19.11.2024

Prof. Simone Ferrero